GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity

Glucagon-like peptide 1 (GLP-1) was initially identified in the early 1980s and since then several therapeutic agents have been discovered for the treatment of diabetes based on the modulation of GLP-1. GLP-1R agonists Exenatide, Lixisenatide, Liraglutide, Dulaglutide, and Albiglutide have been approved for the treatment of type 2 diabetes. This article will review GLP-1R agonist mechanism of action, biology, safety profile of various GLP-1R agonists, and their structure–activity relationships.